Ericka Wong, MD

Ericka Wong, MD, comments on gaps in care in myasthenia gravis and provides take-home messages for physicians treating patients with this condition.

An expert neurologist discusses zilucoplan and other pipeline agents in the treatment of myasthenia gravis.

Dr Ericka Wong discusses recent FDA approval of efgartigimod for myasthenia gravis.

Ericka Wong, MD, discusses challenges and opportunities with new FDA-approved treatments for myasthenia gravis.

An expert neurologist discusses the clinical use of ravulizumab in the treatment of myasthenia gravis.

Dr Ericka Wong discusses the approval of eculizumab in the treatment of myasthenia gravis.

Ericka Wong, MD, discusses the importance of shared decision-making and goal setting when treating a patient with myasthenia gravis.

Expert neurologist discusses pharmacological and nonpharmacological options in the treatment of myasthenia gravis.

Dr Ericka Wong discusses treatment options available to patients with initial myasthenia gravis, patients with acute exacerbation, and patients with refractory myasthenia gravis.

Ericka Wong, MD, discusses the challenges in the treatment of myasthenia gravis and the burden of myasthenia gravis.

A practical approach to initiating and tapering corticosteroids, and the considerations in the selection and monitoring parameters of steroid-sparing agents are crucial to the care of myasthenia gravis.